Please assess the completion status of the following clinical trial:

Trial Title: Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 23 0/7 to 29 6/7 weeks GA~2. Birth weight 501 to 1000g, inclusive~3. 14 to 28 days of life, inclusive~4. 14 day BPD risk score ≥ 50% for death or moderate-severe BPD, calculated using the algorithm on the Neonatal Research Network website (https://neonatal.rti.org/index.cfm?fuseaction=BPDCalculator.start).-~Exclusion Criteria:~1. Major congenital and/or chromosomal anomalies~2. Inability to reach 80ml/kg/day enteral feeds by 28 days of life

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Zinc plus standard of care (Type: ACTIVE_COMPARATOR): Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
- Standard of care only (Type: PLACEBO_COMPARATOR): Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age

Based on this trial design, predict the completion outcome and termination type (if applicable).